secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001104659-24-038686
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics reports FY2023 net loss of $25.8M, cash runway through May 2025
--------------------------------------------------------------------------------

- Net loss of $25.8M ($0.86 per share) for FY2023 vs $21.4M ($0.91 per share) in FY2022.
- Cash and equivalents $29.9M at Dec 31, 2023; NIA grant funds of $67.5M remain available.
- March 2024 follow-on offering raised ~$10.4M net, extending cash runway through May 2025.
- Topline results from Phase 2 SHINE study (Alzheimer's) expected mid-2024; SHIMMER (DLB) in 2H2024.
- R&D expenses rose to $37.2M from $30.3M, mainly due to Phase 2 trial activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924038686/0001104659-24-038686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924038686/tm249736d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-038686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer